BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:06 PM
 | 
Sep 04, 2007
 |  BC Extra  |  Clinical News

NGX-4010 meets Phase III pain endpoint

NeurogesX (NGSX) said its NGX-4010 trans-capsaicin dermal patch met the primary endpoint in a Phase III trial to treat neuropathic...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >